Detalhe da pesquisa
1.
Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma.
Clin Cancer Res
; 30(4): 703-718, 2024 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37695642
2.
Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.
Sci Rep
; 13(1): 2710, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36792625
3.
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.
Cancer Discov
; 12(2): 356-371, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34544752
4.
A high-throughput drug screen reveals means to differentiate triple-negative breast cancer.
Oncogene
; 41(39): 4459-4473, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36008466
5.
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Nat Commun
; 13(1): 5258, 2022 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071033
6.
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Clin Cancer Res
; 28(20): 4536-4550, 2022 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921524
7.
Evidence for a link between TNFRSF11A and risk of breast cancer.
Breast Cancer Res Treat
; 129(3): 947-54, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21541702
8.
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.
Genome Med
; 12(1): 78, 2020 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32907621
9.
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Clin Cancer Res
; 26(14): 3720-3731, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32220884
10.
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Mol Cancer Ther
; 18(4): 771-779, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30837298
11.
Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.
Cancer Res
; 79(16): 4258-4270, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31213465
12.
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.
J Exp Med
; 215(7): 1913-1928, 2018 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880484
13.
Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.
Nat Cell Biol
; 20(8): 990, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29674681
14.
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.
Nat Cell Biol
; 20(2): 211-221, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29358704
15.
Modulation of telomere protection by the PI3K/AKT pathway.
Nat Commun
; 8(1): 1278, 2017 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29097657
16.
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.
Stem Cell Reports
; 8(5): 1392-1407, 2017 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28457887
17.
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Nat Commun
; 13(1): 6928, 2022 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376284
18.
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Cancer Res
; 76(8): 2301-13, 2016 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27020857
19.
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
PLoS One
; 10(6): e0131241, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26107737
20.
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Cancer Res
; 72(11): 2879-88, 2012 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22496457